Description
Anti-FAP Antibody, Non-Fucosylated (BioBet-230ZP) is a humanized monoclonal IgG1, κ antibody against FAP. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Unknown
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced FAP antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
FAP
Full Name
Fibroblast Activation Protein Alpha
Background
The protein encoded by this gene is a homodimeric integral membrane gelatinase belonging to the serine protease family. It is selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue sarcomas. This protein is thought to be involved in the control of fibroblast growth or epithelial-mesenchymal interactions during development, tissue repair, and epithelial carcinogenesis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2014]
Alternative Names
Sibrotuzumab; 216669-97-5; BIBH 1; humanized F19; FAP; fibroblast activation protein, alpha; seprase; DPPIV; integral membrane serine protease; 170 kDa melanoma membrane-bound gelatinase; FAPA; DKFZp686G13158;
Gene ID
2191
UniProt ID
Q12884
Cellular Localization
Plasma membrane, Extracellular region or secreted
Involvement in Disease
Diseases associated with FAP include Breast Ductal Carcinoma and Melanoma.
Function
The cell surface glycoprotein serine protease is involved in the degradation of extracellular matrix, and is involved in cellular processes such as tissue remodeling, fibrosis, wound healing, inflammation and tumor growth. Plasma membranes and soluble forms exhibited post-proline cleave endopeptidase activity, which clearly favored the Alabama/Ser-Gly-Pro-Ser/Asn Ala consensus sequence and other substrates alpha-2-antiplasmin SERPINF2 and SPRY2. It can also degrade gelatin and heat-denatured type I collagen, but cannot degrade native type I and IV collagen, vibrating protein, tendin, laminin, fibronectin, fibrin or casein. There is also dipeptidyl peptidase activity, which shows that it can hydrolyze the two residues of prolyl bonds. The n-terminal synthetic dipeptide substrate provides the penultimate residue proline, and prefers Ala-Pro, Ile-Pro, Gly-Pro, Arg-Pro Pro- Pro. The natural neuropeptide hormones used for dipeptidyl peptidase are neuropeptide Y (NPY), peptide YY (PYY), substance P (TAC1) and brain natriuretic peptide 32 (NPPB). The plasma membrane form related to DPP4, PLAUR or integrins participates in the extracellular proteolysis of extracellular matrix (ECM), and promotes cell adhesion, migration and invasion through ECM. Play a role in tissue remodeling during development and wound healing. Participate in the invasion of ECM by malignant melanoma tumor cells. Enhance tumor growth and progression by increasing angiogenesis, collagen fiber degradation and cell apoptosis, and by reducing the immune system's anti-tumor response. By degrading proteoglycan, it promotes the infiltration of glioma cells through the brain parenchyma. It regulates cell proliferation and survival in a manner independent of serine protease activity, and acts as a tumor suppressor in melanocytes. 发送反馈 历史记录
Post-translational modifications
N-glycosylated. The N-terminus may be blocked.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
BioBet-230ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to FAP. Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer. It binds to FAP.
Antibody Indication
Unknown
